Initial clinical data are anticipated from mid-2026.

MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK Marks Zelluna's transition from preclinical to clinical-stage development ...

2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...

In this study, the researchers analyzed more than 275 million T-cell receptor sequences from over 2,200 individuals and used artificial intelligence ...

T cells are a critical part of the adaptive immune system that respond to pathogens, tumors, or play a key role in autoimmune diseases. A T cell recognizes potential targets through its T cell ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...

Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

Zelluna plans to initiate the first clinical trial of ZI-MA4-1 subject to regulatory approval (CTA approval), marking a key milestone in the clinical development of the company's off-the-shelf TCR-NK ...

Jefferson Health oncologist Jennifer Johnson had exhausted all the standard treatment options for her 49-year-old patient with esophageal cancer, who was likely to die within months. Surgery, ...